Dapagliflozin (10mg) & GLIDAPAFLOZIN 10  Tablet - Steris Healthcare PVT LTD………

May 14, 2024

Introduction

GLIDAPAFLOZIN 10 is a once-daily oral antidiabetic tablet containing Dapagliflozin 10 mg, a highly selective Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor. It is used to improve glycemic control in adults with Type 2 Diabetes Mellitus (T2DM) and is also proven to provide cardiovascular and renal benefits beyond glycemic control.This tablet can be used as monotherapy or in combination with metformin, DPP-4 inhibitors, insulin, or other oral antidiabetics depending on individual patient requirements.

Composition

Each film-coated tablet contains:

  • Dapagliflozin – 10 mg

Mechanism of Action

Dapagliflozin acts by:

  • Inhibiting SGLT2 transporters in the proximal renal tubules

  • Preventing reabsorption of filtered glucose into the bloodstream

  • Promoting urinary glucose excretion, which leads to lower blood glucose levels

  • Working independent of insulin, making it effective even in insulin resistance

  • Providing modest weight loss and blood pressure reduction

Therapeutic Indications

GLIDAPAFLOZIN 10 is indicated for:

Clinical Benefits

Clinical Benefit Explanation
HbA1c Reduction Average reduction of 0.5% to 1%
Weight Loss Due to calorie loss in urine
BP Reduction Mild systolic BP drop (2-5 mmHg)
Heart Failure Benefit Reduced hospitalization risk
Renal Protection Slows CKD progression

Dosage and Administration

Parameter Details
Dose 10 mg once daily
Route Oral
Timing Can be taken with or without food
Swallow whole Do not crush or split

Renal dosing:

  • Not recommended in eGFR < 25 mL/min/1.73m²

  • Continue cautiously in moderate CKD (eGFR ≥25) with nephrologist advice

Side Effects of Dapagliflozin 10 mg

Common:

  • Increased urination

  • Genital fungal infections (especially in females)

  • Urinary tract infections (UTIs)

  • Thirst, dry mouth

  • Mild hypotension or dizziness

Rare but serious:

  • Euglycemic diabetic ketoacidosis (EDKA)

  • Fournier’s gangrene (necrotizing fasciitis of the perineum)

  • Hypotension in volume-depleted patients

  • Dehydration

Contraindications

  • Type 1 Diabetes Mellitus

  • History of diabetic ketoacidosis

  • Severe renal impairment (eGFR < 25)

  • Hypersensitivity to dapagliflozin

  • Conditions associated with lactic acidosis (e.g., severe infections, dehydration)

Drug Interactions

Drug/Class Interaction
Diuretics Additive effect on volume depletion
Insulin/SUs May increase hypoglycemia risk
Lithium Monitor levels (can affect renal clearance)
ACE inhibitors Monitor BP and renal function

Monitoring Parameters

  • Blood glucose levels and HbA1c

  • Renal function (eGFR) baseline and periodically

  • Hydration status

  • Signs of UTIs or genital infections

  • Ketones if unexplained nausea, vomiting, or malaise occur

Storage Guidelines

  • Store below 25°C, in a dry place

  • Protect from light and moisture

  • Keep out of reach of children

Frequently Asked Questions (FAQs)

Q1. What is the best time to take GLIDAPAFLOZIN 10?

Anytime of day, but try to take it at the same time daily. Can be taken with or without food.

Q2. Can GLIDAPAFLOZIN 10 cause hypoglycemia?

Not by itself. However, when used with insulin or sulfonylureas, the risk increases.

Q3. Does Dapagliflozin cause weight loss?

Yes, a modest weight loss of 2–3 kg over 6 months may occur due to urinary glucose loss.

Q4. Is it safe in kidney disease?

It is not recommended in eGFR < 25 mL/min/1.73m². Renal function should be monitored regularly.

Q5. What to do if I miss a dose?

Take it as soon as remembered. If it's near the next dose, skip the missed dose. Do not double the dose.

Conclusion

GLIDAPAFLOZIN 10 offers a powerful, once-daily oral therapy for Type 2 Diabetes Mellitus, especially in patients requiring glycemic control, weight management, cardiorenal protection, or those at high cardiovascular risk. Its excellent efficacy-safety balance and convenience make it a cornerstone therapy in the modern diabetes treatment paradigm.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW

SHARE WITH